SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rosenberg AM. Uveitis associated with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1987; 16: 15873.
  • 2
    Key SW III, Kimura SJ. Iridocyclitis associated with juvenile rheumatoid arthritis. Am J Ophthalmol 1975; 80: 4259.
  • 3
    Merriam JC, Chylack LT, Albert DM. Early onset pauciarticular juvenile rheumatoid arthritis: a histopathologic study. Arch Ophthalmol 1983; 101: 108592.
  • 4
    Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol 2003, 14: 3958.
  • 5
    Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ Jr, Fink CW, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29: 27481.
  • 6
    Chylack LT. The ocular manifestations of juvenile rheumatoid arthritis. Arthritis Rheum 1977; 20: 21723.
  • 7
    Olson NY, Lindsley CB, Godfrey WA. Nonsteroidal anti-inflammatory drug therapy in chronic childhood iridocyclitis. Am J Dis Child 1988; 142: 128992.
  • 8
    De Benedetti F, Ravelli A, Martini A. Cytokines in juvenile rheumatoid arthritis. Curr Opin Rheumatol 1997; 9: 42833.
  • 9
    Eberhard BA, Laxer RM, Andersson U, Silverman ED. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 1994; 96: 2606.
  • 10
    Mangge H, Kenzian H, Gallistl S, Neuwirth G, Liebmann P, Kaulfersch W, et al. Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995; 38: 21120.
  • 11
    Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, et al. Oral tolerance: immunologic mechanisms and treatment of murine and human organ specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12: 80937.
  • 12
    Rizzo LV, Miller-Rivero NE, Chan C-C, Wiggert B, Nussenblatt RB, Caspi RR. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest 1994; 157: 43947.
  • 13
    Eberhard BA, Laxer RM, Andersson U, Silverman ED. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 1994; 96: 2606.
  • 14
    Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double blind, placebo-controlled trial. N Engl J Med 1992; 326: 10439.
  • 15
    Wells HG. Studies on the chemistry of anaphylaxis (III): experiments with isolated proteins, especially those of the hen's egg. J Infect Dis 1911; 8: 14771.
  • 16
    Thompson HSG, Staines NA. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin Exp Immunol 1986; 64: 5816.
  • 17
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Eng J Med 2000; 343: 158693.
  • 18
    Dick AD, McMenamin PG, Korner H, Scallon BJ, Ghrayeb J, Forrester JV, et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 1996; 26: 101825.
  • 19
    Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci 1996; 37: 22118.
  • 20
    Kasner L, Chan CC, Whitcup SM, Gery I. The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1993; 34: 29117.
  • 21
    Santos LM, Marcos CM, Gallardo Galera JM, Gomez Vidal MA, Colanges Estevez E, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001; 33: 2515.
  • 22
    Lovell DJ, Giannini EH, Whitmore JB, Soffes L, Finck BK. Safety and efficacy of tumor necrosis factor receptor p75 Fc fusion protein (Etanercept: ENBREL™) in polyarticular course juvenile rheumatoid arthritis [abstract]. Arthritis Rheum 1998; 41(9 Suppl ): S130.
  • 23
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. New Engl J Med 2000; 342: 7639.
  • 24
    Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis. Ophthalmology 2001; 108: 11349.
  • 25
    Larkin G, Lightman S. Mycophenolate mofetil: A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999; 106: 3704.
  • 26
    Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 14115.
  • 27
    Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003; 121: 43740.